Analysis of a safety run-in cohort from NIVEAU, a phase 3 study for patients with aggressive Non-Hodgkin lymphoma in first relapse or progression not eligible for High-Dose Chemotherapy (HDT) testing Nivolumab in combination with (R)-GemOx

0 avis

Analysis of a safety run-in cohort from NIVEAU, a phase 3 study for patients with aggressive Non-Hodgkin lymphoma in first relapse or progression not eligible for High-Dose Chemotherapy (HDT) testing Nivolumab in combination with (R)-GemOx

Archive ouverte

Edité par CCSD -

International audience

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration.

Archive ouverte | Frontzek, F. | CCSD

International audience. Progression or relapse in the central nervous system (CNS) remains a rare but mostly fatal event for patients with diffuse large B-cell lymphoma (DLBCL). In a retrospective analysis of 5189 p...

Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/ DSHNHL analysis.

Archive ouverte | Thieblemont, C. | CCSD

International audience. Most patients with diffuse large B-cell lymphoma (DLBCL) can be cured with immunochemotherapy such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Patients ...

BCL2 expression but not MYC and BCL2 coexpression predicts survival in elderly patients with diffuse large B-cell lymphoma independently of cell of origin in the phase 3 LNH03-6B trial

Archive ouverte | Petrella, T. | CCSD

International audience

Chargement des enrichissements...